February 2014, 14:478
Date: 23 Feb 2014
Systematic Reviews to Ascertain the Safety of Diabetes Medications
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control. With this expansion has come a flurry of concerns about the safety of these antihyperglycemic agents, concerns that affect judgments about the risk/benefit balance of therapy. Some of these safety signals have been identified through the synthesis of existing research evidence. Thus, it has become important for clinicians and clinical policymakers to understand the strengths and limitations of systematic reviews and meta-analyses in determining the safety of diabetes medications. In this paper, we highlight key safety concerns with diabetes medications and discuss the role evidence synthesis plays in each, with special attention to its strengths and limitations.
This article is part of the Topical Collection on Pharmacologic Treatment of Type 2 Diabetes
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Centers for Disease Control and Prevention. Increasing prevalence of diagnosed diabetes—United States and Puerto Rico, 1995–2010. Morb Mortal Wkly Rep. 2012;61:918–21.
Green S, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter 1: Introduction. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. N Engl J Med. 2014;369:1285–7. doi:10.1056/NEJMp1309610.
•Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–201. doi:10.1001/archinternmed.2010.207. This meta-analysis included the largest trial of cardiovascular safety for rosiglitazone and confirmed an increased of myocardial infarction and heart failure associated with rosiglitazone use.PubMedCrossRef
•Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet. 2009;373:2125–35. doi:10.1016/s0140-6736(09)60953-3. This is the largest randomized trial looking at the cardiovascular safety of rosiglitazone and is at the center of the controversy surrounding the cardiovascular safety of rosiglitazone.PubMedCrossRef
Egger M, Smith GD, Altman D. Systematic reviews in health care: meta-analysis in context. London: BMJ books; 2008.
••Department of Health and Human Services. Advisory committee meeting for NDA 21071 Avandia (rosiglitazone maleate) tablet July 13 and 14, 2010. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218491.htm. This document details the 2010 FDA review of rosiglitazone, within which the limitations of the RECORD trial are highlighted.
Food and Drug Administration. FDA requires removal of certain restrictions on the diabetes drug Avandia. November 25, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm.
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–89. doi:10.1016/s0140-6736(05)67528-9.PubMedCrossRef
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534–9. doi:10.1001/jamainternmed.2013.2720.PubMedCrossRef
••Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ. 2013;346:f3680. doi:10.1136/bmj.f3680. This is an investigative report written by an editor from the BMJ that highlights the concerns around the safety of glucagon supressing drugs.
Meinert CL. Clinical trials: design, conduct and analysis. New York, New York: Oxford University Press; 2012.
Meinert CL. Clinical Trials Dictionary: Terminology and usage recommendations. Hoboken, NJ: John Wiley & Sons, Inc.; 2012.
U.S. Food and Drug Administration. FDA’s Sentinel Initiative. 2013. http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm. Accessed 19 Sept 2013.
- Systematic Reviews to Ascertain the Safety of Diabetes Medications
Current Diabetes Reports
- Online Date
- February 2014
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Systematic review
- Diabetes medications
- Industry Sectors
- Author Affiliations
- 1. Knowledge and Evaluation Research Unit, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
- 2. Mayo Graduate School, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
- 3. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
- 4. Division of Preventive, Occupational and Aerospace Medicine, Division of Health Care Policy and Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA